You are here

Patient preference for treatment of chronic phase CML: Phase ll Quantitative Survey- Reminder

This survey has recruited 15 participants so far, another 7 are needed to fill the initial quota.
Recruitment closes on 30th May so if you are interested in participating then please contact
Denise Salinger
email: Denise@denisesalinger.com
tel: 020 8905 3016

Patient preference for treatment of chronic phase CML: Phase ll Quantitative Survey

*Participants must be resident in the UK and over 18 years of age and....
*Willing to provide informed consent.
*Must be diagnosed with Chronic Myeloid Leukaemia in chronic phase (cp-CML).
*Currently treated with either, imatinib (Glivec), dasatinib (Sprycel) or nilotinib (Tasigna).
*The survey will be conducted in English.
*Participants must therefore have adequate written and oral fluency in English.
*Have access to Internet to complete online survey.
*Survey will take 15- 20 minutes to complete.

See post at top of page for further details

Sandy

Hi Sandy,

I spoke to Denise on Monday afternoon and completed the survey on Tuesday morning. It was all pretty simple and straightforward. Denise was very nice and the survey was nothing intrusive and mainly a series of scenario based questions. It probably took me around 10 minutes to do it.

I'd encourage anyone that can to take part - it all helps doesn't it?

Thanks,
Debs.